As of December 31, 2023, the Company had cash and cash equivalents of $13.4 million. As of December 31, 2022, the Company had cash and cash equivalents and marketable securities of $26.4 million. The Company expects that its current cash and cash equivalents will support its ongoing operating activities through the third quarter of 2024. This cash runway guidance is based on the Company’s current operational plans and excludes any additional funding and any business development activities that may be undertaken. Indaptus continues to assess all financing options that would support its corporate strategy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INDP:
- Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
- Indaptus announces results from second cohort in Phase 1 INDP-D101 trial
- Indaptus Therapeutics launches new social media initiative to provide education
- Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
